○ Human lifespan benefit: not established by the compiled studies. Included records: no healthy-aging lifespan RCT — imetelstat is a telomerase INHIBITOR approved for a disease (lower-risk MDS); it is the opposite direction from anti-aging telomerase activation and is not an aging therapy

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Oligonucleotide telomerase inhibitor (cancer drug) — the honesty foil

Also known as: imetelstat, GRN163L, RYTELO

Relationship to telomere biology: Imetelstat is a lipid-conjugated oligonucleotide that binds the RNA template of telomerase (TERC) and INHIBITS the enzyme. It is included here deliberately as the honesty foil: the only FDA-approved telomerase drug points in the OPPOSITE direction from anti-aging 'activation' — it shuts telomerase down to treat cancer.

Regulatory status

US FDA approved RYTELO on 6 June 2024 for adults with low/intermediate-1 risk MDS and transfusion-dependent anemia requiring ≥4 red-cell units over 8 weeks, with inadequate/lost ESA response or ESA ineligibility. This telomerase inhibitor is a disease treatment, not an aging approval.

Mechanism

By inhibiting telomerase, imetelstat preferentially depletes the malignant clones in MDS/myelofibrosis that depend on telomerase. In the IMerge Phase 3 trial it improved red-cell transfusion independence versus placebo. This is why the field's only approved telomerase drug treats cancer by SUPPRESSING the enzyme. See /telomerase-cancer-paradox.

Animal lifespan evidence

Animal lifespan evidence: none in this dataset

No animal lifespan study in this dataset. Imetelstat INHIBITS telomerase and is approved to treat a blood cancer, not to extend life.

This is separate from human lifespan evidence, which is none for every intervention on this site. A mouse lifespan result is not a human lifespan result, and a telomere change is not a lifespan result in either species.

Evidence — Human (Phase 3 RCT — disease population) verify: source publication identified; see evidence and limitations

Species / population	178 patients in randomized IMerge Phase 3 (118 imetelstat, 60 placebo), with transfusion-dependent IPSS low/intermediate-1 MDS and inadequate/lost ESA response or ESA ineligibility. Registry NCT02598661 covers more than this randomized phase and must not supply its cohort denominator.
Exposure, route, schedule	Intravenous imetelstat every 4 weeks.
Comparator / duration	Randomized, double-blind, placebo-controlled.
Endpoint / numeric result	FDA reported ≥8-week red-cell transfusion independence in 39.8% versus 15.0% and ≥24-week independence in 28.0% versus 3.3% (imetelstat vs placebo). FDA approval on 6 June 2024 is for adults requiring ≥4 red-cell units/8 weeks with insufficient/lost ESA response or ineligibility, not all lower-risk MDS.
What it did NOT establish	This is cancer/hematology treatment via telomerase INHIBITION in a disease population. It is not an aging trial, and it is the opposite mechanistic direction from the 'telomerase activation' anti-aging narrative.

Negative or null findings

Imetelstat is an INHIBITOR, not an activator — reading it as a 'telomerase longevity drug' inverts its actual mechanism and indication.
It carries significant hematologic toxicity (cytopenias); it is a disease treatment, not a wellness intervention.

Studies on this page

IMerge Phase 3: imetelstat (telomerase INHIBITOR) in lower-risk MDS (Platzbecker et al., 2024)

Imetelstat (telomerase INHIBITOR)